FES PET/CT scan for uterine cancer spread
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 study tests how well a special PET/CT scan (called FES PET/CT) can find uterine cancer and its spread. It may help doctors see where cancer is active, which can guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have uterine cancer that has come back or spread (or a tumor that hasn’t been operated on) and it has been proven by a biopsy or standard imaging
- Your usual scans must show at least one spot outside the liver
- You must be willing to sign informed consent and take part in study steps
- If you recently used tamoxifen or fulvestrant, you may need time to stop before the scan (about 8 weeks or 28 weeks, respectively)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well an FTT PET/CT scan can detect and measure metastatic (spread) prostate cancer. It may help your care team decide on the best next treatment plan, especially if you need to change or start therapy.
This trial tests a special PET scan called FES to see if it can detect estrogen receptors in brain metastases. It may help doctors better target treatment for people with ER+ breast cancer that has spread to the brain.
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
This trial is testing a special PET scan (18F-FES PET/CT) to see if it can find distant cancer spread in women with a slow-growing, estrogen receptor-positive, stage III breast cancer. The goal is to find out whether this imaging test can detect hidden metastases better than standard scans.
This early-phase study uses a special PET scan (FES PET/CT) to better match tamoxifen treatment to people with estrogen-receptor–positive breast cancer that has spread. It aims to see whether the scan results can help optimize tamoxifen use and potentially improve outcomes.
This trial tests a new type of PET/CT scan that uses a special tracer to find endometriosis lesions. It may help surgeons see exactly where the disease is, which could lead to more complete treatment.
Hear when a new Uterine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.